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Abstract Mona is an SH3 and SH2 domain-containing adapter
molecule that is induced during monocytic differentiation. Here
we have first shown that M-CSFR is the major Mona partner in
M-CSF signaling, the interaction being mediated through
tyrosine 697 of the receptor. Next we asked whether Mona
expression would alter the Ras/MAP kinase pathway since
Mona is a likely competitor of Grb2 for binding to M-CSFR. We
found that M-CSF induced late and massive phosphorylation of
ERK molecules in Mona-expressing myeloid cells compared
to non-expressing cells. These results suggest that Mona
expression might modify M-CSF signaling during monocytic
differentiation. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Macrophage colony-stimulating factor (M-CSF) is the prin-
cipal regulator of monocyte/macrophage development [1].
Biological e¡ects of M-CSF are mediated by a speci¢c recep-
tor (M-CSFR), encoded by the c-fms proto-oncogene [2], the
expression of which is restricted to committed monocytic cells
in the bone marrow [3]. Ectopically expressed M-CSFR can
induce M-CSF-dependent proliferation of ¢broblasts [4] or of
hematopoietic cells [5^7], and di¡erentiation towards the
monocyte/macrophage lineage of myeloid progenitor cell lines
such as FDC-P1 [8] or NFS-60 [9].
Ligand binding to the extracellular domain of M-CSFR
induces receptor dimerization and autophosphorylation on
several cytoplasmic tyrosine residues, of which three can re-
cruit Src homology 2 (SH2) domain-containing signaling mol-
ecules [10]. Tyrosine 559, located in the juxtamembrane re-
gion, interacts with Src family members [11]. In the kinase
insert (KI), tyrosine 697 interacts with two related adapters,
Grb2 [12] and Mona [13], and tyrosine 721 binds either to the
p85 adapter subunit of phosphatidylinositol 3P kinase (PI3K)
[14] or to phospholipase C-Q2 (PLCQ2) [15]. Thus it appears
that two M-CSFR autophosphorylation sites, tyrosines 697
and 721, are bivalent. Following binding on tyrosine 721,
PI3K transduces an anti-apoptotic signal through PKB/Akt
activation [16], whereas PLCQ2 controls commitment of mye-
loid cells to terminal monocytic di¡erentiation [15]. Binding of
Grb2 to tyrosine 697 allows translocation of the nucleotide
exchange factor Sos to the plasma membrane then activation
of the Ras-MAP kinase (MAPK) pathway in ¢broblasts and
hematopoietic cells [12,17]. However, the role of Mona in
myeloid cells is still unclear.
We originally identi¢ed Mona as a molecule that interacts
with activated M-CSFR, using a yeast two-hybrid screen [13].
Mona contains one SH2 domain and two SH3 domains
closely related to the corresponding domains of Grb2, and a
unique proline-rich region. It is expressed only in hemato-
poietic cells, including monocytes and T lymphocytes [13].
In lymphoid cells, Mona (also called Gads, Grf-40 or GrpL)
interacts with SLP-76 to activate the nuclear factor of acti-
vated T cells (NF-AT) and is believed to play an important
role in TCR-mediated signaling [18^20]. In the monocytic
lineage, Mona expression is restricted to maturing cells and
circulating monocytes [13]. Moreover, Mona overexpression
strongly inhibits M-CSF-dependent monocyte/macrophage
production in vitro [13]. Collectively, these data strongly sug-
gested the involvement of Mona in M-CSF signaling and/or
monocytic di¡erentiation.
Since Mona could compete with Grb2 for binding onto
Tyr-697 [13], the present studies were undertaken to clarify
the role of Mona in M-CSF signaling. The Mona SH2 do-
main appears to have a speci¢city similar to that of Grb2,
thereby binding to M-CSFR [13], LAT [18,19], Shc and the
Bcr-Abl fusion protein [21]. Since Grb2 associates with both
M-CSFR and Shc [17], we compared the interactions of Mona
and Grb2 with M-CSFR or Shc in M-CSF-stimulated myeloid
cells. Here we show that Mona binds essentially to M-CSFR
and very weakly to Shc and that Mona overexpression results
in sustained and elevated MAPK activation in response to M-
CSF.
2. Materials and methods
2.1. Cells
The M-CSFR-expressing derivatives of FDC-P1 cells (FD/Fms) [22]
used in these studies were maintained in Iscove’s modi¢ed Dulbecco’s
medium (IMDM; Life Technologies, Gaithersburg, MD, USA) sup-
plemented with 10% fetal bovine serum (FBS, Roche Diagnostics,
Mannheim, Germany) and 1% X63-IL-3 cell conditioned medium
[23] as a source of interleukin-3 (IL-3). To obtain FD/Y697F/Mona
cells, FD/Y697F cells were cultivated on a layer of i-2/L(Mona)SN
producer cells [13] for 24 h, then selected for 1 week by 1 mg/ml of
G418 (Life Technologies).
Supernatants from Sf9 insect cells expressing murine recombinant
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M-CSF from a baculovirus vector [24] were used as a source of M-
CSF. Original stock contained 150 000 U/ml M-CSF, one unit being
able to stimulate formation of one colony from 50 000 bone marrow
cells plated in standard agar cultures.
For immunoprecipitation studies, cells were washed in IMDM and
cultivated for 15 h in IMDM supplemented with 1% FBS and 1%
X63-IL-3 cell conditioned medium. After two washes in IMDM, cells
were resuspended in IMDM-10% FBS then stimulated or not with M-
CSF (15 000 U/ml) for 90 s at 37‡C or 1 h at 4‡C, as speci¢ed in the
¢gure legends. For MAPK activation studies, cells were washed in
IMDM, incubated for 3 h in IMDM supplemented with 1% FBS,
then stimulated or not with M-CSF (15 000 U/ml) for various dura-
tions as indicated in the ¢gure legends.
2.2. Immunoprecipitation and immunoblotting
Polyclonal rabbit antisera to Mona (#L1) and the murine Fms
cytoplasmic domain (#4599B) have been previously described
[13,25]. Polyclonal rabbit antiserum to Shc (#1403H) and monoclonal
antibody to phosphotyrosine (clone 4G10) were kindly provided Drs.
L.R. Rohrschneider (Fred Hutchinson Cancer Research Center, Seat-
tle, WA, USA) and P. Dubreuil (INSERM U119, Marseille, France),
respectively. Monoclonal antibody to murine Grb2 was from Trans-
duction Laboratories. Anti-pERK and anti-pan-ERK were from San-
ta Cruz Biotechnologies (Santa Cruz, CA, USA).
Cells were lysed as previously described [13]. For immunoprecipi-
tation, equalized cell lysates were incubated with antibodies, as speci-
¢ed below, for 1 h at 4‡C. Subsequently, protein G-Sepharose beads
(Sigma, Saint-Louis, MO, USA) were added to samples for 1 h in-
cubation at 4‡C with gentle rotation. Immune complexes were washed
¢ve times in lysis bu¡er, and bound proteins eluted by boiling for
5 min in Laemmli sample bu¡er. Immunoblotting procedures have
been described previously [13].
2.3. GST fusion proteins and in vitro binding assays
Glutathione-S-transferase (GST)^Mona SH2 fusion protein has
been previously described [13]. To obtain GST-Mona fusion protein,
the Mona cDNA insert obtained by PCR from L(Mona)SN retroviral
vector [13] was fused to GST cDNA in the pGEX3 vector (Amersham
Pharmacia Biotech). Pull-down experiments were conducted as de-
scribed in [13].
3. Results
3.1. Mona associates with M-CSFR in vivo
Using pull-down experiments, we previously showed that
Mona expressed as a GST fusion protein binds to phosphor-
ylated tyrosine 697 of M-CSFR [13]. To examine this inter-
action in a physiological context, co-immunoprecipitation ex-
periments were performed. FDC-P1 cells expressing both M-
CSFR and Mona (FD/wtFms/Mona cells) were stimulated or
not with M-CSF. Anti-Mona immunoprecipitates from cell
lysates were probed with either anti-Fms or anti-phosphotyr-
osine antibodies. Fig. 1A shows that M-CSFR was detected in
immunoprecipitates only when cells were stimulated with M-
CSF (left panel) and also suggests that M-CSFR is the major
tyrosine-phosphorylated molecule associating with Mona in
M-CSF stimulated cells (right panel). Furthermore, substitut-
ing tyrosine 697 for phenylalanine was su⁄cient to almost
completely abrogate Mona^M-CSFR interaction (Fig. 1B).
3.2. Association of Mona and Shc is marginal in FDC-P1 cells
M-CSF stimulation of FD/wtFms cells results in rapid Shc
phosphorylation and association with Grb2 through its SH2
domain [17]. As shown in Fig. 2A, full-length Mona, as well
as its SH2 domain, expressed as GST fusion proteins associ-
ated with both phosphorylated isoforms of Shc, p52Shc and
p46Shc in a M-CSF-dependent manner. Unexpectedly, anti-
Mona immunoprecipitates from FD/wtFms/Mona cells con-
tained only small amounts of Shc (Fig. 2B). Non-precipitated
material was then used for immunoprecipitation with anti-Shc
antibodies, revealing the presence of abundant Shc-Grb2 com-
plexes in material not retained with anti-Mona antibodies
(Fig. 2B). To con¢rm these data, Shc was immunoprecipitated
by anti-Shc antibody from lysates from M-CSF-stimulated
FD/wtFms/Mona cells and immunoprecipitates were probed
using anti-Mona or anti-Grb2 antibodies. Grb2 was readily
detected in these immunoprecipitates whereas Mona was not
detectable (Fig. 2C). These results show that, in vivo, Shc
associates with Grb2 rather than with Mona following M-
CSF stimulation.
3.3. The kinetics of MAPK activation is altered in
FD/Fms/Mona cells
M-CSF triggers rapid activation of the Ras/Raf-1/MEK/
MAPK pathway in myeloid 32D cells [26]. These e¡ects
may be mediated through association of Grb2/Sos complexes
to activated M-CSFR and Shc [17]. Since Mona associates
preferentially with M-CSFR, we asked whether this would
impinge on MAPK activation in response to M-CSF. FD/
Fig. 1. Mona associates with activated M-CSFR. A: Starved FD/wtFms/Mona cells were stimulated (+) or not (3) for 1 h at 4‡C with M-
CSF (15 000 U/ml). Cell lysates were incubated with anti-Mona antibody, then immunoprecipitates were run on a 7.5% polyacrylamide gel,
blotted and probed with anti-phosphotyrosine antibody or anti-Fms antibody as indicated. B: FD/wtFms/Mona cells and FD/Y697F/Mona
cells were treated as above, except that anti-Mona immunoprecipitates were probed with anti-phosphotyrosine antibody.
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wtFms and FD/wtFms/Mona cells were therefore stimulated
with M-CSF for di¡erent durations, and activation of the
endogenous MAPK p42 (ERK2) and p44 (ERK1) was deter-
mined using a speci¢c antibody detecting the phosphorylated
form of ERK1 and ERK2 (pERK). Total ERK expression
being monitored using a pan-ERK antibody, pERK bands
were quantitated and normalized to signals obtained with
anti-pan ERK antibody (Fig. 3).
In FD/wtFms cells, M-CSF clearly induced biphasic activa-
tion of MAPK (Fig. 3A, left panel). The early phase occurred
between 1 min 30 s and 10 min whereas the late phase started
after 1 h, MAPK activation returning to basal levels between
30 min. and 1 h after the addition of M-CSF (Fig. 3B). In
sharp contrast, M-CSF-stimulated FD/wtFms/Mona cells ex-
hibited profound changes in the kinetics and magnitude of
MAPK activation especially during the second wave (Fig.
3A, right panel ; Fig. 3B). Firstly, FD/Fms/Mona cells main-
tained a high level of MAPK activation between 30 min and
4 h of M-CSF stimulation. Secondly, pERK levels at between
1 and 15 h of stimulation were much higher in FD/wtFms/
Mona cells than in FD/wtFms cells (Fig. 3B). These results
were con¢rmed in three independent experiments (Fig. 3C).
Interestingly, FD/wtFms and FD/wtFms/Mona cells showed
identical kinetics of MAPK phosphorylation in response to
IL-3 (data not shown), suggesting that Mona alters MAPK
phosphorylation through recruitment to activated M-CSFR.
4. Discussion
This study investigated the role of Mona in M-CSFR sig-
naling, using myeloid FDC-P1 cells ectopically expressing M-
CSFR (FD/wtFms cells) or M-CSFR and Mona (FD/wtFms/
Mona cells). Expression of M-CSFR confers upon FDC-P1
cells the property of di¡erentiating to macrophages in re-
sponse to M-CSF, thus providing a valuable model for study-
ing the M-CSF signal in a nearly physiological context
[8,15,17].
Mona and Grb2 SH2 domains exhibit identical speci¢city in
vitro for binding to M-CSFR [13] or Shc [21]. Indeed, we have
shown here that Mona interacts in vivo with M-CSFR via
phosphorylated tyrosine 697, like Grb2, as previously sug-
gested [13]. However, we have also demonstrated that Shc
preferentially associates with Grb2 in vivo, its association
with Mona being marginal (Fig. 2). Thus, in myeloid progen-
itor cells, Mona associates with M-CSFR upon M-CSF stim-
ulation whereas Grb2 binds to both M-CSFR and Shc. Grb2
exists in a constitutive complex with Sos in FD/wtFms cells
[17]. Upon M-CSF stimulation, preformed Grb2-Sos com-
plexes bind to phosphorylated M-CSFR and Shc and both
types of complex may contribute to activation of the Ras-
MAPK pathway [17]. Previous investigations and data re-
ported here combine to suggest that Mona and Grb2 might
have di¡erent roles in M-CSFR signaling. Firstly, Mona se-
lectively binds to M-CSFR via its SH2 domain whereas Grb2
binds to both M-CSFR and Shc. Secondly, Mona binds to
SLP-76 but not to Sos in vivo whereas Grb2 binds to Sos, not
to SLP-76 [18,20]. Finally, time-course studies have revealed
that FD/wtFms/Mona cells exhibit sustained and increased
MAPK activation in response to M-CSF compared to control
FD/wtFms cells (Fig. 3).
Fig. 2. Analysis of the interaction between Mona and Shc in FD/wtFms/Mona cells. A: Lysates of FD/wtFms/Mona cells, stimulated (+) or
not (3) for 1 h at 4‡C with M-CSF (15 000 U/ml), were mixed with GST-Mona full-length (Mona) or GST^Mona SH2 (SH2) fusion proteins
immobilized on glutathione^Sepharose. Bound proteins were run on a 12% polyacrylamide gel, blotted and probed with anti-Shc antibody.
B: Starved FD/wtFms/Mona cells were stimulated (+) or not (3) for 90 s at 37‡C with M-CSF (15 000 U/ml). Lysates were used for immuno-
precipitation with anti-Mona antibody. Immunoprecipitates were run on a 7.5% polyacrylamide gel, blotted and probed with anti-Mona anti-
body or anti-Shc antibody. Supernatants were used for a second immunoprecipitation with anti-Shc antibody and precipitated proteins were
then immunoblotted with anti-Shc antibody or anti-Grb2 antibody. C: As for B, but lysates were used for a single immunoprecipitation with
anti-Shc antibody. Immunoprecipitates were immunoblotted with anti-Shc antibody, anti-Mona antibody or anti-Grb2 antibody.
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Persistent MAPK activation has been associated with the
di¡erentiation process in neuronal [27] or megakaryocytic [28]
di¡erentiation. Similarly, expression of the activated Ha-ras
oncogene leads to macrophage di¡erentiation in FDC-P1 cells
[29]. However, we here observed that macrophage di¡erentia-
tion proceeded identically in FD/wtFms and FD/wtFms/
Mona cells (data not shown), although they di¡ered markedly
in their levels of activated MAPK (Fig. 3). It is noteworthy
that FD/wtFms cells show a rapid, uniform and dramatic
di¡erentiation response to M-CSF [22] which could preclude
observation of any positive e¡ects on the di¡erentiation of
FD/wtFms/Mona cells.
M-CSF clearly stimulated two waves of MAPK activation
in FD/wtFms and FD/wtFms/Mona cells (Fig. 3). Temporal
regulation of MAPK activation notably involves dual specif-
icity phosphatases [30] which are then potential targets of
signaling pathways downstream of Mona. Alternatively,
Mona may operate on signaling pathways that positively reg-
ulate MAPK activation. It has been shown recently that PI3K
activity is essential to IL-3-triggered MAPK activation in
FDC-P1 cells [31]. Tyrosine phosphatases SHP-1 and SHP-2
may also be involved in the Ras-mediated activation of
MAPK through as yet undetermined mechanisms [32,33].
Thus, our current studies, which aim at identifying Mona
partners, should help to elucidate the role of the protein in
M-CSFR signaling and also shed further light on the regula-
tion of MAPK activation during monocytic di¡erentiation.
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